Bremen D - Search Results

1

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D. Müller T, et al. Among authors: bremen d. J Neural Transm (Vienna). 2006 Oct;113(10):1441-8. doi: 10.1007/s00702-006-0442-5. Epub 2006 Apr 11. J Neural Transm (Vienna). 2006. PMID: 16604302 Clinical Trial.

2

Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.

Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D. Müller T, et al. Among authors: bremen d. Mov Disord. 2006 Mar;21(3):332-6. doi: 10.1002/mds.20717. Mov Disord. 2006. PMID: 16211593

3

Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.

Müller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, Goetze O. Müller T, et al. Among authors: bremen d. Clin Neuropharmacol. 2006 Mar-Apr;29(2):61-7. doi: 10.1097/00002826-200603000-00001. Clin Neuropharmacol. 2006. PMID: 16614536 Clinical Trial.

4

Entacapone improves complex movement performance in patients with Parkinson's disease.

Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D. Müller T, et al. Among authors: bremen d. J Clin Neurosci. 2007 May;14(5):424-8. doi: 10.1016/j.jocn.2006.02.008. Epub 2006 Jun 21. J Clin Neurosci. 2007. PMID: 16790350 Clinical Trial.

5

Levodopa therapy with entacapone in daily clinical practice: results of a post-marketing surveillance study.

Kupsch A, Trottenberg T, Bremen D. Kupsch A, et al. Among authors: bremen d. Curr Med Res Opin. 2004 Jan;20(1):115-20. doi: 10.1185/030079903125002775. Curr Med Res Opin. 2004. PMID: 14741081

6

Entacapone increases and prolongs the central effects of l-DOPA in the 6-hydroxydopamine-lesioned rat.

Gerlach M, van den Buuse M, Blaha C, Bremen D, Riederer P. Gerlach M, et al. Among authors: bremen d. Naunyn Schmiedebergs Arch Pharmacol. 2004 Nov;370(5):388-94. doi: 10.1007/s00210-004-0984-8. Epub 2004 Oct 20. Naunyn Schmiedebergs Arch Pharmacol. 2004. PMID: 15502970

7

[Analysis of direct costs in therapy of Parkinson disease].

Keller S, Kessler T, Meuser T, Fogel W, Bremen D, Jost WH. Keller S, et al. Among authors: bremen d. Nervenarzt. 2003 Dec;74(12):1105-9. doi: 10.1007/s00115-003-1582-6. Nervenarzt. 2003. PMID: 14647911 German.

8

[Indirect costs in idiopathic Parkinson's disease].

Barth F, Baum B, Bremen D, Meuser T, Jost WH. Barth F, et al. Among authors: bremen d. Fortschr Neurol Psychiatr. 2005 Apr;73(4):187-91. doi: 10.1055/s-2004-830106. Fortschr Neurol Psychiatr. 2005. PMID: 15806436 German.

9

Hypericin-induced apoptosis of human malignant glioma cells is light-dependent, independent of bcl-2 expression, and does not require wild-type p53.

Weller M, Trepel M, Grimmel C, Schabet M, Bremen D, Krajewski S, Reed JC. Weller M, et al. Among authors: bremen d. Neurol Res. 1997 Oct;19(5):459-70. Neurol Res. 1997. PMID: 9329022

10

Cooperative interception of neuronal apoptosis by BCL-2 and BAG-1 expression: prevention of caspase activation and reduced production of reactive oxygen species.

Schulz JB, Bremen D, Reed JC, Lommatzsch J, Takayama S, Wüllner U, Löschmann PA, Klockgether T, Weller M. Schulz JB, et al. Among authors: bremen d. J Neurochem. 1997 Nov;69(5):2075-86. doi: 10.1046/j.1471-4159.1997.69052075.x. J Neurochem. 1997. PMID: 9349553 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters